Oral Cancer in HSCT Pediatric Patients Arising on GVHD: A Comprehensive Review.
Tiziana CantileNoemi CoppolaFederica CanforaDaniela AdamoElvira RuoppoMichele Davide MignognaStefania LeuciPublished in: Cancers (2022)
After haematopoietic stem cell transplantation and a history of GVHD, the risk of developing secondary malignancies, including oral cancer, is higher. This risk increases with time post-transplantation; therefore, pediatric patients undergoing HSCT, who have long-term survival chances, are in a high-risk category. The aim of this review is to provide data on HSCT, GVHD, clinical manifestations, histological features and treatment of oral cancer, and outcomes in HSCT pediatric patients, affected by oral GVHD, who have been developed OSCC. Descriptive statistics were used to validate data. Fifteen studies on a total of 33 patients were selected. Data on oral cancer showed that the tongue was the most frequently involved site (13 pts; 39.39%), followed by the floor of the mouth (4 pts; 12.12%), and buccal mucosa (4 pts; 12.12%). Oral squamous cell carcinoma was the histological feature reported. There were 19 (57.58%) deaths occurring between 2 and 46.5 months after OC diagnosis. Eleven patients survived with a median follow-up of 34 months. Considering the high risk of developing oral cancer, a conventional oral examination every 6 months is recommended for HSCT pediatric patients who have developed GVHD.
Keyphrases
- stem cell transplantation
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- patients undergoing
- ejection fraction
- newly diagnosed
- hematopoietic stem cell
- electronic health record
- high dose
- prognostic factors
- stem cells
- type diabetes
- acute lymphoblastic leukemia
- mesenchymal stem cells
- acute myeloid leukemia
- metabolic syndrome
- low dose
- young adults
- cell therapy
- skeletal muscle
- data analysis
- glycemic control